Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI.

Arch Pathol Lab Med. 2018 Oct 30. doi: 10.5858/arpa.2018-0336-CP. [Epub ahead of print]

PMID:
30376374
2.

Whole tumor section quantitative image analysis maximizes between-pathologists' reproducibility for clinical immunohistochemistry-based biomarkers.

Barnes M, Srinivas C, Bai I, Frederick J, Liu W, Sarkar A, Wang X, Nie Y, Portier B, Kapadia M, Sertel O, Little E, Sabata B, Ranger-Moore J.

Lab Invest. 2017 Dec;97(12):1508-1515. doi: 10.1038/labinvest.2017.82. Epub 2017 Aug 14.

3.

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

Hou Y, Nitta H, Wei L, Banks PM, Portier B, Parwani AV, Li Z.

Breast Cancer Res Treat. 2017 Nov;166(2):447-457. doi: 10.1007/s10549-017-4453-8. Epub 2017 Aug 10.

PMID:
28799059
4.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2017 Jul;31(7):1658. doi: 10.1038/leu.2017.77. Epub 2017 Mar 21.

PMID:
28322226
5.

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.

Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.

Cancer. 2017 Jun 15;123(12):2230-2239. doi: 10.1002/cncr.30592. Epub 2017 Feb 13.

6.

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.

Calhoun BC, Portier B, Wang Z, Minca EC, Budd GT, Lanigan C, Tubbs RR, Morrison LE.

BMC Cancer. 2016 Aug 30;16:695. doi: 10.1186/s12885-016-2743-x.

7.

Conserving wildlife amongst the cotton fields. A third of a century of experience at the Nazinga Game Ranch, Burkina Faso.

Bouché P, Lejeune P, Bailly V, Muyle M, Zinque MH, Mercier A, Cornélis D, Lungren C, Portier B, Marchal A, Renault F, Yaméogo D, Kafando P, Sawadogo P, Vermeulen C.

Environ Monit Assess. 2016 Jul;188(7):437. doi: 10.1007/s10661-016-5388-y. Epub 2016 Jun 27.

PMID:
27350287
8.

Emerging Biomarkers in Personalized Therapy of Lung Cancer.

Cagle PT, Raparia K, Portier BP.

Adv Exp Med Biol. 2016;890:25-36. doi: 10.1007/978-3-319-24932-2_2. Review.

PMID:
26703797
9.

Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.

Liu C, Pepper K, Hendrickson H, Cagle PT, Portier BP.

Arch Pathol Lab Med. 2016 Jul;140(7):690-3. doi: 10.5858/arpa.2015-0419-OA. Epub 2015 Nov 24.

PMID:
26599807
10.

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.

Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP.

Arch Pathol Lab Med. 2016 Jun;140(6):529-35. doi: 10.5858/arpa.2015-0261-SA. Epub 2015 Nov 4.

PMID:
26536055
11.

Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.

Driver BR, Portier BP, Mody DR, Deavers M, Bernicker EH, Kim MP, Teh BS, Santacruz JF, Kopas L, Munden RF, Cagle PT.

Arch Pathol Lab Med. 2016 Apr;140(4):312-7. doi: 10.5858/arpa.2015-0361-OA. Epub 2015 Oct 2.

PMID:
26430808
12.

[Reaction on 'Areas of interest within psychiatry: a gain or a loss?'].

Honig A, Verwey B, Kromkamp M, Sierink D, Gordijn M, Leue C, Portier B, Scherders M.

Tijdschr Psychiatr. 2015;57(8):626. Dutch. No abstract available.

13.

A new ever-evolving paradigm.

Cagle PT, Olsen RJ, Portier BP, Takei H, Bernard DW.

Arch Pathol Lab Med. 2015 Apr;139(4):446-7. doi: 10.5858/arpa.2014-0629-ED. No abstract available.

PMID:
25822762
14.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA.

Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.

PMID:
25442074
15.

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN.

Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22.

16.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2014 Nov;28(11):2155-64. doi: 10.1038/leu.2014.119. Epub 2014 Apr 4. Erratum in: Leukemia. 2017 Jul;31(7):1658.

17.

Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.

Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP.

Am J Clin Pathol. 2014 Apr;141(4):559-72. doi: 10.1309/AJCP1JUGQMW7ZNTL.

PMID:
24619758
18.

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN.

Mol Cancer Ther. 2014 May;13(5):1142-54. doi: 10.1158/1535-7163.MCT-13-0770. Epub 2014 Jan 16.

19.

Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disorders.

Tubbs RR, Wang H, Wang Z, Minca EC, Portier BP, Gruver AM, Lanigan C, Luo Y, Cook JR, Ma XJ.

Am J Clin Pathol. 2013 Nov;140(5):736-46. doi: 10.1309/AJCPJTWK07FSABRJ.

PMID:
24124155
20.

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.

Portier BP, Minca EC, Wang Z, Lanigan C, Gruver AM, Downs-Kelly E, Budd GT, Tubbs RR.

Oncotarget. 2013 Oct;4(10):1662-72.

21.

Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

Parekh P, Kamble S, Zhao N, Zeng Z, Portier BP, Zu Y.

Biomaterials. 2013 Nov;34(35):8909-17. doi: 10.1016/j.biomaterials.2013.07.099. Epub 2013 Aug 19.

22.

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.

Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP.

Mod Pathol. 2014 Feb;27(2):314-27. doi: 10.1038/modpathol.2013.122. Epub 2013 Aug 2.

23.

Fast modal method for crossed grating computation, combining finite formulation of Maxwell equations with polynomial approximated constitutive relations.

Portier B, Pardo F, Bouchon P, Haïdar R, Pelouard JL.

J Opt Soc Am A Opt Image Sci Vis. 2013 Apr 1;30(4):573-81. doi: 10.1364/JOSAA.30.000573.

PMID:
23595315
24.

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR.

J Mol Diagn. 2013 May;15(3):341-6. doi: 10.1016/j.jmoldx.2013.01.004. Epub 2013 Mar 13.

PMID:
23499337
25.

Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.

Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, Vo HT, Ma XJ, Luo Y, Budd GT, Tubbs RR.

J Mol Diagn. 2013 Mar;15(2):210-9. doi: 10.1016/j.jmoldx.2012.10.003. Epub 2013 Jan 8.

PMID:
23305906
26.

Mason's rule and signal flow graphs applied to subwavelength resonant structures.

Estruch T, Pardo F, Portier B, Jaeck J, Derelle S, Haidar R.

Opt Express. 2012 Nov 19;20(24):27155-62. doi: 10.1364/OE.20.027155.

PMID:
23187571
27.

Reversible switching of the interparticle distance in DNA-templated gold nanoparticle dimers.

Lermusiaux L, Sereda A, Portier B, Larquet E, Bidault S.

ACS Nano. 2012 Dec 21;6(12):10992-8. doi: 10.1021/nn304599d. Epub 2012 Nov 8.

PMID:
23121650
28.

Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.

Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR.

Mod Pathol. 2013 Jan;26(1):1-9. doi: 10.1038/modpathol.2012.123. Epub 2012 Aug 17.

29.

A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA.

Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, Liu X.

Diagn Mol Pathol. 2012 Sep;21(3):127-33. doi: 10.1097/PDM.0b013e3182461cc3.

PMID:
22847155
30.

Diagnosis of BK viral nephropathy in the renal allograft biopsy: role of fluorescence in situ hybridization.

Wang Z, Portier BP, Hu B, Chiesa-Vottero A, Myles J, Procop GW, Tubbs RR.

J Mol Diagn. 2012 Sep;14(5):494-500. doi: 10.1016/j.jmoldx.2012.04.004. Epub 2012 Jul 5.

PMID:
22771425
31.

From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma.

Portier BP, Gruver AM, Huba MA, Minca EC, Cheah AL, Wang Z, Tubbs RR.

N Biotechnol. 2012 Sep 15;29(6):665-81. doi: 10.1016/j.nbt.2012.03.011. Epub 2012 Apr 6. Review.

PMID:
22504737
32.

Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification.

Gruver AM, Portier BP, Tubbs RR.

Arch Pathol Lab Med. 2011 May;135(5):544-57. doi: 10.1043/2010-0734-RAIR.1. Review.

PMID:
21526953
33.

Mixed epithelial and stromal tumor of the kidney.

Portier BP, Hansel DE, Zhou M, Maclennan GT.

J Urol. 2009 Apr;181(4):1879-80. doi: 10.1016/j.juro.2009.01.004. Epub 2009 Feb 23. No abstract available.

PMID:
19233412
34.

Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression.

Portier BP, Taglialatela G.

J Biol Chem. 2006 Dec 29;281(52):40493-502. Epub 2006 Nov 7.

35.

Rapid assay for quantitative measurement of apoptosis in cultured cells and brain tissue.

Portier BP, Ferrari DC, Taglialatela G.

J Neurosci Methods. 2006 Jul 15;155(1):134-42. Epub 2006 Mar 23.

PMID:
16563518
36.

Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2.

Massaad CA, Portier BP, Taglialatela G.

J Biol Chem. 2004 Dec 24;279(52):54470-8. Epub 2004 Oct 6.

37.

A transcript map of the chromosome 19q-arm glioma tumor suppressor region.

Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN, Jenkins RB.

Genomics. 2000 Feb 15;64(1):44-50.

PMID:
10708517
38.

The human glia maturation factor-gamma gene: genomic structure and mutation analysis in gliomas with chromosome 19q loss.

Peters N, Smith JS, Tachibana I, Lee HK, Pohl U, Portier BP, Louis DN, Jenkins RB.

Neurogenetics. 1999 Sep;2(3):163-6.

PMID:
10541589
39.

Thermoregulatory response to wearing encapsulated protective clothing during simulated work in various thermal environments.

Payne WR, Portier B, Fairweather I, Zhou S, Snow R.

Am Ind Hyg Assoc J. 1994 Jun;55(6):529-36.

PMID:
8017293

Supplemental Content

Loading ...
Support Center